Abstract
Background:
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a novel betacoronavirus that was first reported in Saudi Arabia 2012. The majority of infected cases were reported in Saudi Arabia too. Extracorporeal membrane oxygenation (ECMO) is an option as a rescue therapy for patients with refractory hypoxemia and has been successfully used in young patients with severe ARDS secondary H1N1 influenza with refractory hypoxemia. Aim: We conducted a retrospective study to determine the mortality rate of severe ARDS secondary to MERS-CoV infection in response to ECMO therapy in our adult ICU.
Methods:
A retrospective analysis of data from all patients admitted to our adult 23-bed mixed ICU with MERS-CoV infection who developed severe ARDS and been mechanically ventilated between March 1, 2013 and August 30, 2016.
Results:
During the period from March 1, 2013 and August 30, 2016, 32 patients were admitted with severe ARDS secondary to MERS-CoV infection (mean age 54 ± 21 years, 25 [78.1%] males). Bilateral pulmonary infiltrates were reported in all patients. Invasive mechanical ventilation and ECMO therapy was applied in all patients and vasopressor therapy in 26 (81.2%) patients during the ICU stay. Twenty-four (75%) patients died in the ICU. Non-survivors were older and/or had high APACHE II scores on admission.
Conclusions:
Severe ARDS secondary to MERS-CoV infection is associated with high mortality. ECMO therapy was associated with better survival rates and outcomes in younger patients and the patients who had lower APACHE II scores.
Get full access to this article
View all access options for this article.